Clinical trial · Interventional
Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)
The Feasibility and Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Monitoring Patients With Intracranial Metastasis Treated With Stereotactic Radiosurgery (SRS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Upwards of 40% of cancer patients will develop brain metastases during their illness, most of which become symptomatic. The burden of brain metastases impacts the quality and length of survival. Thus the management of brain metastases is a significant health care problem. Standard treatment options include stereotactic radiosurgery and/or whole brain radiation. There is a great interest in studying the association between the functional characteristics of tumors - such as tumour hypoxia and lactate accumulation - and clinical outcomes in order to guide management. These characteristics may predict future tumor behavior and stratify risk of therapy failure. Hyperpolarized 13C MR imaging is a novel functional imaging technique that uses 13C-labeled molecules, such as pyruvate, and MRS to image in vivo tissue metabolism. There is significant clinical heterogeneity in patients with brain metastasis due to differences in underlying tumour biology. Biochemical differences in tumour metabolism have been shown to correlate with response to therapy. While the significance of tissue hypoxia for radiosensitivity has been established for years, the impact of lactate accumulation on radiosensitivity has only recently been recognized. Studies have shown that tissue lactate levels correlate with radioresistance in several human tumours. Hyperpolarized 13C pyruvate MRS has been shown in numerous pre-clinical studies and a recent clinical study to have great potential as a metabolic imaging tool. Our study seeks to establish the role of hyperpolarized 13C MRS in characterizing the metabolic features of intracranial metastasis. The results of this study will provide insight into intracranial metastatic disease signatures with MR spectroscopy and determine if there is added benefit for incorporation of this new technique into future clinical MRI protocols. If the technique can accurately differentiate between aggressive and indolent tumours based on MR spectroscopic patterns, hyperpolarized 13C MRS may have wide-ranging utility in the future. In the era of personalized medicine, the ability of imaging tests to predict response to therapy would open the door for individualized treatment options specific to each patient's disease biology.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperpolarized 13C-Pyruvate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Control Participants Part I
- description
- A MRI with injection of hyperpolarized 13C pyruvate.
- interventionNames
- Drug: Hyperpolarized 13C-Pyruvate
- type
- EXPERIMENTAL
- label
- Intracranial Metastasis Part II
- description
- MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
- interventionNames
- Drug: Hyperpolarized 13C-Pyruvate
- type
- EXPERIMENTAL
- label
- Intracranial Metastasis Part III
- description
- MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate following radiation treatment. MRI with injection of hyperpolarized 13C pyruvate following radiation treatment if adverse radiation effect is identified on post-SRS follow-up images.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Part I (Controls) Group A * Participants of all ethnic groups/race categories (≥18yrs old) * Informed consent Group B * Male participants of all ethnic groups/race categories (between the age of 18-39) * Informed consent Group C * Female participants of all ethnic groups/race categories (between the age of 18-39) * Informed consent Group D * Male participants of all ethnic groups/race categories (between the age of 40-59) * Informed consent Group E * Female participants of all ethnic groups/race categories (between the age of 40-59) * Informed consent Group F * Male participants of all ethnic groups/race categories (≥60 yrs old) * Informed consent Group G * Female participants of all ethnic groups/race categories (≥60 yrs old) * Informed consent Group H and I * Male or female participants of all ethnic groups/race categories (≥18 yrs old) * Informed consent Group J * Male or female participants of all ethnic groups/race categories (≥60 yrs old) * Informed consent * Diagnosed with mild cognitive impairment Group K * Male or female participants of all ethnic groups/race categories (≥60 yrs old) * Informed consent * Diagnosed with mild Alzheimer's disease Group L * Male or female participants of all ethnic groups/race categories (≥18 years of age) * Informed consent Group M * Male or female participants of all ethnic groups/race categories (≥18 years of age) * Informed consent Part II \& III * Adult participants of all ethnic groups/race categories (age ≥18 yrs old) * Radiographic diagnosis of brain metastases and pathological confirmation of a solid cancer primary * Metastatic brain tumor amenable to Stereotactic radiosurgery or radiotherapy * Participants on dexamethasone must be on a stable dose at the time of baseline MRI and 1-5 days post-SRS MRI * Estimated survival more than 6 months * Informed consent Exclusion Criteria: * Prior brain radiotherapy for the specific index or lesion to be imaged in the study * For groups B to I, L, and M only: Montreal Cognitive Assessment (MoCA) score \<26 * The participant will also be asked to complete the standard MRI safety screening questionnaire, prior to their research scan and participation in the study. * Contraindications to MRI including: * Participants weighing \>136 kg (weight limit for the scanner tables) * Participants with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices not compatible with MRI. * Pregnant * Claustrophobia to the extent that the participant cannot stay in the MRI for 45-60 minutes * Known adverse reactions to the contrast agent Gd-DTPA * Inability to lie still for 45-60 minutes * Participants with a high risk factor for nephrogenic systemic fibrosis (NFS). * Participant declines the procedure or further procedures; * Participant is not well enough to undergo MRI scanning; * Participant is unable to complete the MRI procedure for any reason or is non-compliant with MRI requirements. * For groups J and K, a \<1 lacunar infarct or any cortical subcortical infarct or moderate to severe white matter disease * For groups J and K, any other structural brain lesion that could affect cognition
References
Publications (0)
Data not yet available